摘要
目的系统评价痰热清注射液治疗手口足病的临床疗效及安全性。方法计算机检索PubMed、he Cochrane Library、EMbase、CBM、CNKI、VIP和WanFang Data等数据库,查找相关随机对照试验,检索时限均从建库至2013年2月。按纳入与排除标准筛选文献、提取数据和评价纳入研究的方法质量后,采用RevMan 5.2.7软件进行Meta分析。结果共纳入痰热清vs.利巴韦林12个RCT共1 258例患者;痰热清联合利巴韦林vs.利巴韦林的RCT 27个,共3 289例患者。Meta分析结果显示:痰热清与利巴韦林相比,痰热清治疗手足口病的有效率更高[OR=5.03,95%CI(3.28,7.71),P<0.000 01],患者的退热时间[MD=–1.09,95%CI(–1.51,–0.68),P<0.000 01]、疱疹消退时间[MD=–0.90,95%CI(–1.20,–0.60),P<0.000 01]以及治愈时间[MD=–1.76,95%CI(–2.52,–0.99),P<0.000 01]比使用利巴韦林治疗更短,差异均具有统计学意义。痰热清联合利巴韦林与利巴韦林相比,联合用药在总有效率[OR=5.32,95%CI(4.02,7.06),P<0.000 01]、退热时间[MD=–1.32,95%CI(–1.63,–1.01),P<0.000 01]、疱疹消退时间[MD=–0.5,95%CI(–0.98,0.2),P<0.000 01]以及治愈时间[MD=–1.41,95%CI(–1.83,–0.98),P<0.000 01]上更有优势,其差异均有统计学意义。间接比较分析结果提示痰热清联合利巴韦林vs.单用痰热清治疗手足口病在总有效率、退热时间、疱疹消退时间以及治愈时间上的差异均无统计学意义。结论本研究结果提示痰热清联合利巴韦林与单用痰热清治疗手足口病的临床疗效相比其差异无统计学意义,两者的临床疗效均优于单用利巴韦林。
Objective To systematically review the effectiveness and safety of Tanreqing for curing the hand-foot-mouth disease. Methods Such databases as PubMed, EMbase, CENTRAL, CBM, CNKI, VIP and WanFang Data are electronically searched to collect the randomized controlled trials （RCTs） on the effectiveness and safety of Tanreqing for hand-foot-mouth disease till February 2013. According to the inclusion and exclusion criteria, literature was screened, data were extracted, and the methodological quality of included studies was also assessed. Then, meta-analysis was performed using RevMan 5.2.7 software. Results Twelve RCTs on Tanreqing versus ribavirin involving 1 258 cases and 27 RCTs on Tanreqing plus ribavirin versus ribavirin involving 3 289 cases were included. The results of meta-analysis showed that, compared to ribavirin, Tanreqing has higher total efficiency in the treatment of hand-foot-mouth disease （OR=5.03, 95%CI 3.28 to 7.71, P〈0.000 01）, cooling time （MD= –1.09, 95%CI –1.51 to –0.68, P〈0.000 01）, simplex regression time （MD= –0.90, 95%CI –1.20 to –0.60, P〈0.000 01）, and healing time （MD= –1.76, 95%CI –2.52 to –0.99, P〈0.000 01）, with significant differences. Compared to ribavirin, the group of Tanreqing plus ribavirin has higher total efficiency on treatment of hand-foot-mouth disease （OR=5.32, 95%CI 4.02 to 7.06, P〈0.000 01）, cooling time （MD= –1.32, 95%CI –1.63 to –1.01, P〈0.000 01）, simplex regression time （MD= –0.5, 95%CI –0.98 to –0.2, P〈0.000 01）, and healing time （MD= –1.41, 95%CI –1.83 to –0.98, P〈0.000 01）, with significant differences. The results of indirect comparative analysis showed that, there was no significant difference in the treatment options of Tanreqing plus ribavirin and Tanreqing alone concerning total efficiency, cooling time, simplex regression time, and healing time. Conclusion The study shows that Tanreqing alone and Tanreqing plus ribavirin are similar for curing the hand-foot-mouth disease, and both groups have better clinical effectiveness than ribavirin alone.
出处
《中国循证医学杂志》
CSCD
2013年第12期1446-1454,共9页
Chinese Journal of Evidence-based Medicine
关键词
痰热清
利巴韦林
手足口病
META分析
间接比较
系统评价
随机对照试验
Tanreqing injection
Ribavirin
Hand-foot-mouth disease
Meta-analysis
Systematic review
Rand-omized controlled trial
